Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Massachusetts based Founder operating in the Health Care space. If you think a Founder is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Ed Park
Co-Founder & CEO of Devoted Health
Follow Ed Park:
About Devoted Health: Devoted Health is a healthcare company serving seniors and giving them a health care plan with personal guides and world-class technology.
_______
Brad Cohen
Executive Chairman and Founder of Medcase Health
Brad Cohen is the Executive Chairman and Founder at Medcase Health.
Follow Brad Cohen:
About Brightcom Group (formerly LYCOS Internet Ltd), Edgecase.ai, ESPOT TV, Medcase Health: Medcase’s ever-evolving marketplace of clinicians sits at the intersection between technology and healthcare.
David Yu Zhang
Co-Founder & Head of Innovation of NuProbe
David Zhang, Ph.D., is the Ted Law Jr. Assistant Professor of Bioengineering at Rice University. He is a leading expert in molecular diagnostics and DNA biotechnology, and maintains active collaborations with multiple biotech companies.
Follow David Yu Zhang:
About NuProbe: An early stage molecular diagnostics company.
Peng Yin
Co-Founder, Director of NuProbe
Peng is a Professor in the Department of Systems Biology at Harvard Medical School. He also serves as a Core Faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University, where he co-founded Ultivue. Co-Founder, Director at Torus Biosystems.
Follow Peng Yin:
About Harvard Medical School, NuProbe, Torus Biosystems, Ultivue, Wyss Institute: An early stage molecular diagnostics company.
Yingshuang Chai
Co-Founder & CEO of NuProbe
Yingshuang Chai is a Co-Founder, CEO, and Chairman of the Board of Directors at NuProbe.
Follow Yingshuang Chai:
About NuProbe: An early stage molecular diagnostics company.
Junfeng Luo
Co-Founder & Vice President, R&D – NuProbe, China of NuProbe
Junfeng Luo is a Co-Founder and Vice President of R&D at NuProbe, China.
Follow Junfeng Luo:
About NuProbe: An early stage molecular diagnostics company.
Yundi Chen
Co-Founder of NuProbe
Yundi Chen is a Co-Founder at NuProbe.
Follow Yundi Chen:
About NuProbe: An early stage molecular diagnostics company.
Edwin Kania
Managing Partner & Co-Founder; Chairman Emeritus of Flagship Pioneering
Edwin Kania is a Managing Partner and Co-Founder of Flagship Ventures and served as Chairman of the Board of Directors at Flagship Ventures between 2001 – 2014. Edwin has 33 years of experience in the venture capital industry. Prior to co-founding Flagship Ventures in 2000, Edwin spent 14 years as General Partner of OneLiberty Ventures and of its predecessor firm, Morgan, Holland Ventures. From 1983 – 1984 Edwin served as an Investment Officer at First Capital Corporation of Boston, the venture capital subsidiary of Bank of Boston and previously, as Research Associate at Harvard Business School and as General Manager at J. Cunningham, Inc. Edwin is a frequent speaker on venture capital and entrepreneurship. Edwin earned his undergraduate degree in Physics from Dartmouth College and his MBA from Harvard Business School. While at Dartmouth, Edwin was an All-American Track and Field athlete and a national and collegiate record holder. Throughout his professional career, Edwin has operated both as an investor and as an active partner to entrepreneurs in company building. Edwin’s direct investment experience covers over 100 companies. In addition, Edwin has been intimately involved in the launch and development of more than a dozen companies as the founding, lead or co-lead investor, and on occasion has assumed operating roles in support of management. Several of these companies are now publicly traded while others have been acquired by significant publicly-traded companies. The total value of the companies in which Ed has participated as founding or lead investor is currently several billion dollars. Among the companies for which Ed has served as an active Director are Acceleron Pharma (NASDAQ: XLRN), Adolor (NASDAQ: ADLR), Alere Corp. (purchased by Inverness Medical), Anesta Corp. (NASDAQ: NSTA, purchased by Cephalon), Aspect Medical (NASDAQ: ASPM, purchased by Covidien), AudioLogic (purchased by Cirrus Logic), ChemGenics Pharmaceuticals (purchased by Millennium), Cytyc Corp. (NASDAQ: CYTC), EXACT Sciences (NASDAQ: EXAS), Interactive Supercomputing (acquired by Microsoft), Ontogeny (merged into Curis, NASDAQ: CRIS), PerSeptive Biosystems (NASDAQ: PBIO, purchased by Applera), Somatogen (NASDAQ: SMTG, purchased by Baxter), and VisEn Medical (acquired by PerkinElmer). He was also a founding investor in IDEXX Laboratories (NASDAQ: IDXX) and in TripAdvisor (purchased by InterActive Corp). Currently, Edwin is a Director of Flagship portfolio companies EcoSense Lighting, Oasys Water, Selecta Biosciences, TARIS Biomedical, Tarveda Therapeutics, TransMedics and Visterra, as well as on the Board of DataCore Software. Edwin also serves on the Board of Common Impact, a non-profit organization that connects skilled professionals from global corporations to local, high potential non-profits. Edwin has been a long-time Member of the Board of Directors of MassBio, a not-for-profit organization representing theMassachusetts biopharmaceutical industry and serves as a Member of Harvard Partners’ Innovation Advisory Board and The Johns Hopkins Medicine Alliance for Science and Technology Development.
Follow Edwin Kania:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Noubar Afeyan
Founder & CEO of Flagship Pioneering
Noubar Afeyan is Founder, Senior Managing Partner and Chief Executive Officer at Flagship Ventures, a leading early stage venture capital firm. Noubar also leads the firm’s VentureLabs unit that invents and launches transformative startups. Noubar is a Senior Lecturer at MIT’s Sloan School of Management where he has taught courses on technology-entrepreneurship, innovation and leadership since 2000. Noubar lectures widely in the United States and internationally on diverse topics ranging from entrepreneurship, innovation and venture capital to biological engineering, drug discovery, medical technologies and renewable energy. During his 28-year career as inventor, entrepreneur, CEO and venture capitalist, Noubar has co-founded and helped build over 35 successful life science and technology startups. Noubar was Founder and Chief Executive Officer at PerSeptive Biosystems, a leader in the bio-instrumentation field that grew to over $100M in annual sales within six years from its first sales. After PerSeptive’s acquisition by Perkin Elmer/Applera Corporation in 1998, Noubar was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics. Currently Noubar serves on a number of public and private company boards including CiBO Technologies, Epiva BioSciences, Evelo BioSciences, Joule Unlimited, Kaleido BioSciences, Moderna Therapeutics, Pronutria Biosciences and Seres Therapeutics. Previously, Noubar was a Member of the founding team, Director and Investor in several highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), Adnexus Therapeutics (acquired by Bristol-Myers Squibb) and Affinnova (acquired by AC Nielsen). Noubar received a Technology Pioneer 2012 award from the World Economic Forum in recognition of the breakthrough solar fuel technology being developed at Joule Unlimited. Noubar has served as Chairman of the Global Agenda Council on Chemicals, Advanced Materials and Biotechnology of the World Economic Forum as well as being a member of the Meta-Council on Emerging Technologies. Noubar is a Member of the Board of Overseers of the Boston Symphony Orchestra. In addition, he serves on the board of AmeriaBank and of UWC Dilijan International School, both of Armenia. Previously, Noubar was a Co-Founder and Member of the Board of Directors at National Competitiveness Foundation of Armenia, a private-public partnership dedicated to promoting economic development in the former Soviet Republic of Armenia. In 2008 Noubar received the Ellis Island Medal of Honor, an award granted to outstanding Americans who have distinguished themselves as United States citizens and who have enabled their ancestry groups to maintain their identities while becoming integral parts of American life. Noubar has authored numerous scientific publications and patents since earning his Ph.D. in Biochemical Engineering from MIT in 1987. Cygnal is a best-in-class team of biomedical experts and leaders collaborating to revolutionize how the world treats diseases.
Follow Noubar Afeyan:
About BIND Therapeutics, Cogen Therapeutics, Cygnal Therapeutics, Ensemble Therapeutics, Flagship Pioneering, Generate Biomedicines, Harvard Business School, Indigo, Joule Unlimited Technologies, Laronde, Massachusetts Institute of Technology, Moderna Therapeutics, Omega Therapeutics, Permeon Biologics, Ring Therapeutics, Rubius Therapeutics, Seres Therapeutics: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Nichola Eliovits
Co-Founder, Chief Business Officer of DermBiont
Nick’s investment expertise spans across asset classes with an extensive focus on microbiome oriented companies across all stages of venture capital. Nick is a Managing Partner at Olive Tree Capital; he led his last company through acquisition and has successfully seeded and structured companies across multiple industries. His passion for the Microbiome originates from personal experiences with skin infections and c-diff. Nick graduated with honors from Boston University’s Questrom School of Business and started his career in commodity markets at CPM Group in New York.
Follow Nichola Eliovits:
About DermBiont, Popover: DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases.
Todd Dagres
Chairman and Founder of Liteboxer
Todd Dagres is the Chairman and Founder at Liteboxer.
Follow Todd Dagres:
About Liteboxer, Signpost, Spark Capital: Liteboxer is a provider of a digital fitness platform used to provide an engaging full-body boxing workout.
Jeffrey Morin
Co-Founder and CEO of Liteboxer
Jeffrey Morin is the founder and CEO of Liteboxer.
Follow Jeffrey Morin:
About Liteboxer: Liteboxer is a provider of a digital fitness platform used to provide an engaging full-body boxing workout.
Lanny Sun
Co-Founder & CEO of Silicon Therapeutics
Follow Lanny Sun:
About Silicon Therapeutics: Silicon Therapeutics is a fully integrated drug design, research, and development company.
Geraldine Harriman
CSO & Co-Founder of HotSpot Therapeutics
Geraldine Harriman is the Co-Founder and Chief Scientific Officer of HotSpot Therapeutics.
Follow Geraldine Harriman:
About HotSpot Therapeutics: HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.
Nessan Bermingham
Founder, CEO & currently Exec Chair of Triplet Therapeutics
Nessan Bermingham is founder and CEO of Triplet Therapeutics, Inc. He is a serial biotech entrepreneur and investor who has founded several companies including Triplet, Korro Bio and Intellia Therapeutics, “one of the top 10 biotech start-ups in 2014” and a “Fierce 15 biotech company,” taking the company from concept to IPO and large partnering deals with approximately 200 employees. He has nearly two decades of experience in Life Sciences startups and investments, including small molecules, biologics, medical devices, and diagnostics through venture, public, and secondary markets. As a venture partner at Atlas Venture and managing partner at Omega Funds, he successfully invested in and managed multiple investments across the United States and Europe. Currently he is also a venture partner at Atlas Venture and is Chair of the Board of Directors of F-star and Akrevia Therapeutics. He served as Intellia’s President and CEO from inception until December 2017. Previously he was an independent advisory board member of the California Institute of Regenerative Medicine (CIRM) and MerckSerono KGaA. He received his Ph.D. in Molecular Biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine. He is an avid mountain biker, snowboarder and trail runner. Nessan is co-founder and was previously chief executive officer of Intellia Therapeutics. He led Intellia from seed investment and incubation at Atlas Venture through its IPO and the advancement of its gene editing platform toward clinical development. He has over ten years of experience in life science investing across venture, secondary, and public markets. Previously, Nessan was a partner at Omega Funds and founder of Bio Equity Capital, a healthcare focused special situations firm. Nessan is also co-founder of Tal Medical.
Follow Nessan Bermingham:
About Korro Bio, Triplet Therapeutics: Triplet is developing transformative therapies that treat repeat expansion disorders at their source.
Alexis Borisy
Co-Founder of Blueprint Medicines
Alexis Borisy is the Chairman of the Board of Directors & Co – Founder of Foundation Medicine Inc.He is also a Partner at Third Rock Ventures.Alexis Borisy is a successful biotechnology entrepreneur with 20 years of experience building and operating innovative science-based organizations. Alexis Borisy joined the life sciences venture capital firm Third Rock Ventures in 2009 to focus on the formation, development and strategy of new companies. He co-founded Foundation Medicine and served as the company’s interim CEO through May 2011.Prior to joining Third Rock Ventures, Alexis Borisy founded CombinatoRx in 2000, serving as its Chief Executive Officer and bringing the company public on the NASDAQ. He has raised $750 million in financing and business development deals, and has authored numerous scientific papers and patents. Trained in chemistry and chemical biology at Harvard where he was a Howard Hughes Predoctoral Fellow, Alexis Borisy was honored as the Massachusetts Institute of Technology’s Technology Review Innovator of the Year. He was also chosen as the New England Entrepreneur of the Year in Life Sciences and was honored as a Presidential Scholar.Alexis Borisy’s Undergraduate Degree in Chemistry is from the University of Chicago, and he did his graduate work in the laboratory of Dr. Stuart Schreiber at Harvard University. Alexis Borisy serves on the Board of the Biotechnology Industry Organization, is an Overseer at the Boston Museum of Science, is the Chairman of Forma Therapeutics, and serves on the board of Blueprint Medicines.
Follow Alexis Borisy:
About Blueprint Medicines, Blueprint Medicines, EQRx, Third Rock Ventures: Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.
Nick Lydon
Scientific Founder of Blueprint Medicines
Nick Lydon, Ph.D., is a scientific founder of Blueprint Medicines. Before founding his current consulting company, Granite Biopharma, LLC, Dr. Lydon served as vice president, small molecule drug discovery at Amgen. Prior to joining Amgen, he founded and led Kinetix Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of selective protein kinase inhibitors, a number of which are now advancing through clinical development. Kinetix was acquired by Amgen in 2000. Prior to Kinetix, Dr. Lydon worked at CIBA-GEIGY, in Basel, Switzerland, where he was responsible for the protein kinase inhibitor program. He and his team identified a number of protein kinase inhibitors. The most advanced drug from this program is Gleevec®, a selective Bcr-Abl inhibitor for the treatment of chronic myelogenous leukemia (CML). Dr. Lydon began his pharmaceutical career at Schering-Plough Corporation, where his research involved studies on recombinant alpha, beta and gamma interferons. In 2009, Dr. Lydon was awarded the Lasker-DeBakey Award for Clinical Medical Research for his work on developing Gleevec®, converting a fatal cancer into a manageable chronic condition. Other awards include the Warren Alpert Foundation Prize, the AACR-Bruce F. Cain Memorial Award, and the Charles F. Kettering Prize from the General Motors Cancer Research Foundation for his contributions to the discovery and development of Gleevec®. Dr. Lydon earned a B.S. in biochemistry from the University of Leeds, England, and received his Ph.D. in biochemistry from the Medical Sciences Institute, University of Dundee, Scotland. His thesis involved research work on adenylate cyclase and cAMP dependent protein kinase. Dr. Lydon served as an advisor and member of the board of directors of Ambit BioScience from 2004 to 2009 and assisted in the development of AC220, a FLT3 kinase inhibitor in Phase 2 clinical development in relapsed/refractory acute myeloid leukemia (AML).
Follow Nick Lydon:
About Blueprint Medicines: Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.
Mirza Cifric
Co-Founder & Chief Executive Officer of Veritas Genetics
Follow Mirza Cifric:
About Veritas Genetics, YPO: Veritas Genetics is a provider of a genetic testing platform intended to empower people to live healthier and longer.
Jonathan Zhao
Founder & Managing Director, Asia of Veritas Genetics
Jonathan Y. Zhao, Ph.D. is Co-Founder of Veritas Genetics and serves as its Managing Director of Asia. Jonathan Zhao is responsible for Asia strategy and new products at Amgen and Pfizer. He holds MBA from MIT Sloan and Ph.D. in Chemistry.
Follow Jonathan Zhao:
About Veritas Genetics: Veritas Genetics is a provider of a genetic testing platform intended to empower people to live healthier and longer.
Boris Lipchin
Founder and CEO of BRIO Systems
Boris Lipchin, co-founder and CEO of Brio Systems, Inc.. Boris was previously a co-founder and CTO of Airmada, Inc. before Airmada four years as a flight software engineer, launch operator and GN&C engineer for SpaceX.
Follow Boris Lipchin:
About Brio, BRIO Systems, Techstars: BRIO Systems offers a complete COVID-19 testing system to help employers keep teams safe and businesses on track.
Anna Villarreal
Founder & CEO of LifeStory Health Inc
Leading the first-ever discovery research into the clinical utility of menstrual blood, a recent Proof of Principle study resulted in findings of unique signatures specific to menstrual blood. On-going clinical studies aim to develop the diagnostic science further in order to support our preliminary pipeline. Anna’s resourceful leadership style and entrepreneurial experience has lead LifeStory Health, Inc. through remarkable discoveries and growth in a very short time when compared to most bioscience companies. She attributes this to her steadfast passion for and about Women’s Health. A strong advocate for women’s healthcare, Anna’s pioneering vision to map the menstrual blood proteome through a set of resolute, data-leading principles and an award winning scientific methodology has led to biomarker discovery based on precision medicine. Anna guest lectures for several graduate level programs at Northeastern University including data analytics, chemistry, regulatory affairs, and master’s in business administration. She teaches her own class in the Master’s of Biotechnology Program titled “Women’s Health: Driving Innovation and Cultural Change”. Her advocacy for women’s health continues on her podcast, “Setting the Pace”, in which she and her co-host highlight fellow female innovators.
Follow Anna Villarreal:
About CEOWORLD Magazine, LifeStory Health Inc, NEFC, The Doctor Weighs In: LifeStory Health is a biotech company committed to changing the women’s healthcare market through technology, innovation and vocalization.
Terry Anderton
Founder and CEO of WAGZ
Terry Anderton is the founder and CEO of Wagz and a lifelong dog owner. Terry has a long history of building disruptive and forward-thinking technology companies, including Gemr, a social commerce platform; Trunity, a cloud-based textbook company he took public in 2012; and NitroSecurity, a network security developer acquired by Intel in 2011. Terry has also served as a Senior Sales Executive for Cabletron Systems and McAfee. He started his career leading world wide sales and launching the game of Paintball for the inventor of the game.
Follow Terry Anderton:
About WAGZ: Helping humans stay connected to their dogs through the world’s smartest dog collar.
Shantanu Gaur
Co-Founder & CEO of Allurion Technologies
Shantanu Gaur co-founded Allurion in 2009 during his second year at Harvard Medical School and is our Chief Scientific Officer. A Paul & Daisy Soros Fellow, Shantanu graduated summa cum laude and Phi Beta Kappa from Harvard College with an S.B. in Biology and significant coursework in polymer chemistry. Shantanu graduated from Harvard Medical School in 2013. He grew up in Pittsburgh, Pennsylvania and lives in Cambridge, Massachusetts.
Follow Shantanu Gaur:
About Allurion Technologies, Genetic Alliance: Allurion Technologies develops a medical device for weight loss that can be delivered and removed without surgery or endoscopy.
Garry Choy
Co – Founder of andros
Dr. Garry Choy, MD, MBA, is Q’s Chief Medical Officer. Prior to joining Q he was faculty at Harvard Medical School / Mass General Hospital where he held leadership positions in enterprise and imaging informatics including as Assistant Chief Medical Information Officer, Director of the Medical Imaging Trials Center, and Medical Director for MGH-QPID Analytics. Recipient of a number of grants and awards in applying machine learning to healthcare from the ACR, CRICO, and RSNA. Previously a research scholar focused on advanced imaging techniques at the National Institutes of Health and Howard Hughes Medical Institute. Completed MD from Albert Einstein College of Medicine and residency training at Harvard-based Brigham and Women’s Hospital and Massachusetts General Hospital. Completed MBA from Hopkins, MS in Economic Engineering Systems & Operations Research from Stanford, and BS in Chemical Engineering from Columbia University.
Follow Garry Choy:
About andros, Massachusetts General Hospital, Q Bio: andros is a provider of network management solutions for healthcare organizations.
Nello Mainolfi
Founder, President & CEO of Kymera Therapeutics
Nello Mainolfi is the Founder, President, and Chief Executive Officer at Kymera Therapeutics.
Follow Nello Mainolfi:
About Kymera Therapeutics: Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Derek Lo
Founder and CEO of Medallion
Derek Lo Founder and CEO of Medallion. He was previously co-founder and CEO at Py. He earned his bachelor’s degree in computer science and statistics from Yale University.
Follow Derek Lo:
About Hired, Medallion: Medallion provides a network management platform for the healthcare industry.
Khaled Kteily
Founder & CEO of Legacy
Khaled Kteily is the Founder & CEO of Legacy, a digital fertility clinic for men helping change the outdated view that fertility is a “women’s issue”. Legacy is a graduate of Harvard’s Innovation Labs and Y Combinator, has raised over $20M from top-tier investors like FirstMark Capital & Bain Capital Ventures, as well as celebrities like Justin Bieber and DJ Khaled. The company works with leading insurers, military partners, and clinics in additions to its Direct to Consumer offering. A former healthcare consultant at Oliver Wyman in Toronto, Khaled studied public policy at the Harvard Kennedy School, where he received a full scholarship and graduated with distinction. He previously graduated with a triple concentration from McGill University in Montreal, Canada. Khaled is a member of the Young Presidents Organization (YPO), is an Aspen Ideas Health Scholar, and a World Economic Forum Global Leadership Fellow. He was recently recognized as 40 under 40 by the Arab America Foundation. He serves on the boards of the Harvard Kennedy School’s Center for Public Leadership (Alumni Council) and the Harvard Arab Alumni Association.
Follow Khaled Kteily:
About Legacy: Legacy is a digital fertility clinic for men, founded at Harvard & backed by Y Combinator, FirstMark Capital, Bain Capital and celebrities.
Amy Schulman
Executive Chairman & Co-Founder of Lyndra Therapeutics
Amy Schulman is the Chief Executive Officer at Arsia Therapeutics since August 2014. Arsia, a biotechnology company focused on improving patients’ lives through new modes of drug delivery, and a venture partner at Polaris, a leading venture capital firm with approximately 4 billion under management in August of 2014. Amy joined Polaris Partner’s Boston office as a Healthcare Venture Partner in 2014, simultaneously assuming the role of Chief Executive Officer of Arsia Therapeutics, a Polaris-backed company. In July 2015 Amy co-founded Lyndra where she is Chief Executive Officer and President. Amy is an accomplished business leader, widely recognized for growing and stabilizing global businesses, commitment to people, strategic judgment, and efforts to advance women and promote inclusive workplace cultures. Amy joined Harvard Business School’s Faculty as a Senior Lecturer in July 2014. Prior to that, Amy led Pfizer Inc.’s $4 billion Consumer Healthcare business, which operates in 90 countries and includes well-known brands such as Advil, Centrum and Chapstick. Amy also served as Executive Vice President and General Counsel of Pfizer Inc. Key accomplishments include: revitalization of the ChapStick brand; regulatory filing for Lipitor OTC; rapid growth of Emergen-C and increased Europe profitability. Amy originally joined Pfizer in 2008 as General Counsel and saw the company through its $68 billion acquisition of Wyeth, the largest pharmaceutical acquisition in history. In 2009, Amy spearheaded an innovative approach to engaging outside counsel and became recognized as a leading voice for transforming the billable-hour model and for redefining the value of legal services. Before joining Pfizer, Amy was a Partner at DLA Piper, where she was a Member of the Board and Executive Policy Committees and built and led the international law firm’s mass tort and class-action practice handling some of the most complex legal, scientific and regulatory challenges facing the world’s largest and most reputable companies, including Kraft, Altria, Cisco, GE Healthcare and Pfizer. Amy began her career in litigation with Cleary Gottlieb Steen & Hamilton. Amy’s accomplishments have earned her accolades from leading publications and organizations. In 2013 Fortune magazine named her one of the “50 Most Powerful Women in Business.” That same year, The American Lawyer named her one of the “Top 50 Innovators,” and The National Law Journal named her one of “The 100 Most Influential Lawyers in America.” Amy also has been recognized by The American Bar Association, which honored her with the Margaret Brent Women Lawyers of Achievement award in 2012. In 2009 Forbes magazine included her on its inaugural list of “The World’s Most Powerful Women.” Amy serves on the Boards of Directors of Alnylam Pharmaceuticals, Arsanis, Biosciences, Arsia Therapeutics, BIND Therapeutics, Blue Buffalo, Lyndra, and SQZ Biotech. A Phi Beta Kappa Graduate of Wesleyan University, Amy earned her J.D. from Yale Law School in 1989.
Follow Amy Schulman:
About Arsia Therapeutics, Harvard Business School, Lyndra Therapeutics, Polaris Partners, Suono Bio: Lyndra Therapeutics is a novel technology platform reinventing medicine for a healthier world.
Ravi Ika
President, Founder & Chief Executive Officer of RxAdvance
A noted entrepreneur and an innovator of disruptive business solutions, Ravi Ika founded RxAdvance in 2013 and serves as president and chief executive officer of the full service pharmacy benefit management (PBM) company. He launched RxAdvance to lower pharmacy, specialty and avoidable drug-impacted medical costs and achieve better outcomes, quality and compliance in the new era of value-based health care. The RxAdvance platform Mr. Ika created from the ground up, the Collaborative PBM Cloud™, provides comprehensive automated services for all PBM administrative, clinical, specialty management, care stakeholder engagement, and compliance management functions. It does so in a way never before imagined in the PBM industry. The Collaborative PBM Cloud™ combines pharmacy, medical, and lab information to deliver actionable intelligence. Prescribers receive this real time actionable intelligence at the point of care, pharmacists at point of sale, patients via mobile cloud and payers clinical and pharmacy staff engagement through their workflows. Among the valuable results: Lower costs, optimal utilization, better outcomes, higher quality, greater transparency and rigorous compliance. Mr. Ika envisions a $750 billion PBM market long in need of transformation. The five largest PBMs, which manage over 80% of $300 billion in pharmacy benefit spend, provide limited, siloed services using antiquated, legacy platforms. Their lack of holistic vision introduces an additional $350 billion of avoidable drug-impacted medical costs into U.S. health care. In addition, $100 billion in poorly managed “buy and bill” specialty drug spend needs to be converted to an “authorize and manage” model. More than 15 years ago, Mr. Ika recognized a similar transformational opportunity in health insurance. Industry insiders, challenged to reduce administrative costs by 30% and avoidable medical costs by 20%, saw the goals as unachievable. Mired in paper-based processes, the industry also struggled with a myriad of fragmented, inflexible, and expensive legacy systems. Mr. Ika responded to this opportunity with ikaSystems, an enterprise payer-platform company. Disrupting obsolete paradigms, he delivered unprecedented change long before passage of the Patient Protection and Affordable Care Act. The ikaSystems platform decreased administrative costs for many health insurers by as much as 50% and significantly reduced avoidable medical costs. With these results, ikaSystems raised more than $140mm capital from Providence Equity and Essex Woodland Ventures. Known for building and inspiring world-class teams, Mr. Ika takes a hands-on approach to ensure his clients’ success. Over the years, healthcare industry leaders have come to rely on his vision and talent for creating enterprise platforms that radically disrupt legacy business paradigms and deliver significant value. Mr. Ika has a master’s degree in environmental engineering from Old Dominion University and worked as a research scientist at Harvard University prior to his entrepreneurial career.
Follow Ravi Ika:
About RxAdvance: RxAdvance, a national full service PBM, leverages disruptive Collaborative PBM Cloud™ to manage standard & specialty drug benefits.
Todd Cozzens
Co-Founder & Managing Partner of Transformation Capital
With more than 25 years of experience in the healthcare technology and information systems industry, Todd Cozzens is a senior advisor with Silicon Valley-based Sequoia Capital, a premier venture-capital firm with a long track record in technology investing. Most recently Cozzens served as the CEO of the accountable care solutions unit of Optum, part of UnitedHealth Group. Cozzens co-founded Picis, the leading high acuity information system company. It was Cozzens’ original strategic vision of information systems for the high-acuity care areas of hospitals that drove the company to a 50% annual growth rate over a ten year span and to over 2100 hospital clients. He was named Entrepreneur of the Year by Ernst & Young in 2005. Prior to Picis, Cozzens served as the president of a division of Marquette Medical Systems (now GE Healthcare) and held several other senior management positions, including vice president of sales, from 1983 to 1995. Cozzens is a graduate of Marquette University and the Harvard Business School Executive Program for Management Development. He was a four-time member of the U.S. Olympic Sailing Team from 1980 to 1992.
Follow Todd Cozzens:
About Transformation Capital: Transformation Capital is a growth equity fund 100% focused on innovative healthcare IT and services companies.
Jared Kesselheim
Co-Founder & Managing Partner of Transformation Capital
Jared Kesselheim, MD, brings to Transformation Capital more than fifteen years of investing and clinical experience and has a demonstrated history of identifying compelling companies and helping them realize continued innovation, growth and strong exits. Jared co-founded Transformation Capital’s predecessor management company in 2016 and serves on the boards of six Fund I portfolio companies: Vera Whole Health, Scientist.com, Aktana, Protenus, Groups, and Panalgo. Previously, Jared was at Bain Capital Ventures, where he was a leader of their digital health practice, focusing on investments in digital health as part of an $850 million multi-sector fund. He became a Partner of Bain Capital Ventures in January 2014, having previously served as an Associate and Principal after joining that firm in July 2008. During his time at Bain Capital Ventures, Jared was involved in multiple high growth investments including: Apixio (Board Director), Remedy Partners (Board Observer; acquired by New Mountain Capital in 2019), ABILITY Network (Board Director after being Board Observer; acquired by Summit Partners in 2014 and acquired by Inovalon in 2018), MedHOK (Board Observer; acquired by Hearst in 2016), National Cardiovascular Partners (Board Observer; acquired by Fresenius in 2014), and Liazon (Board Observer, acquired by Towers Watson in 2014). Prior to his investing career, Jared completed a residency in Internal Medicine at Massachusetts General Hospital. As a resident physician, he oversaw a primary care panel of 300 patients and directed care teams within the hospital’s general medical wards and the medical intensive care unit. Jared graduated from Harvard College summa cum laude and Phi Beta Kappa with a degree in Biochemical Sciences, where he also co-wrote the 1997 Hasty Pudding Theatricals musical “Me and My Galaxy.” He also received an MD from Harvard Medical School and an MBA from Harvard Business School where he was a Baker Scholar and an enthusiastic bench warmer for the HBS Club Hockey team. At home in Newton, Massachusetts, Jared and his wife Dara continue to work in vain on developing strategies for preventing their three young boys from treating all furniture as a form of playground equipment.
Follow Jared Kesselheim:
About Transformation Capital: Transformation Capital is a growth equity fund 100% focused on innovative healthcare IT and services companies.
Ryan Boyko
Founder & CEO of Embark
Ryan Boyko is the CEO and co-founder of Embark Veterinary, Inc. Since graduating from Harvard in 2005 with a BA in Computer Science, he has used Big Data analyses to further scientific research and business development across a number of fields before targeting consumer canine genetics. After receiving an MS in Ecology and MA in Evolutionary Anthropology from the University of California at Davis, he worked to develop Big Data retail consulting analytics for Oliver Wyman. He is currently also completing a PhD in the Epidemiology of Microbial Diseases at the Yale School of Public Health. Since 2007, he has worked part time with his brother Adam on understanding the history and genetics of the domestic dog. This work has sent him to over three dozen countries and led to several publications. He has now chosen to pursue advancing canine health and genetic understanding full-time, building a company to put develop and promote the health and genetic understanding of man’s best friend.
Follow Ryan Boyko:
About Embark: Embark offers dog DNA testing that ends preventable diseases in dogs.
Sammy Khalifa
Co-Founder and CTO of Vicarious Surgical
Follow Sammy Khalifa:
About Vicarious Surgical: Vicarious Surgical improves the lives of patients and surgeons by giving access to high quality care through the use of surgical robotics.
Adam Sachs
Co-Founder and CEO of Vicarious Surgical
Follow Adam Sachs:
About Vicarious Surgical: Vicarious Surgical improves the lives of patients and surgeons by giving access to high quality care through the use of surgical robotics.
Helen Adeosun
Founder & CEO of CareAcademy
Helen is CEO and Co-Founder at CareAcademy.com. She is passionate about caregiving and the impact that the right caregiver can have on families. Prior to this, Helen had worked with Teach for America, Boston Public Schools, and Pearson Education as well as a number of companies focused on caregiving issues. Care Academy was born out of her own experience as a nanny and she hopes that sittercycle.com is a place to continuously learn and share with current and future nannies. She holds a B.A. from the University of Notre Dame and an EdM. from the Harvard Graduate School of Education.
Follow Helen Adeosun:
About CareAcademy: Online training empowering senior care professionals to deliver the highest caliber of service and improve the lives of older adults.
Alicia Chong Rodriguez
Co-Founder and CEO of Bloomer Health Tech
Alicia Chong Rodriguez is the founder and CEO of Bloomer Tech. She holds two master’s degrees in engineering and management/integrated design and electrical engineering and computer science (EECS) from Massachusetts Institute of Technology (MIT).
Follow Alicia Chong Rodriguez:
About Bloomer Health Tech: Bloomer Tech uses everyday fabrics and machine learning for personalized detection, monitoring, and treatment of chronic diseases.
Elizabeth Pattullo
Chairman and Founder of Beacon Health Strategies
Elizabeth Pattullo, one of Beacon’s founders, is responsible for all strategic and business development activities. Creating the business concept of delivering client-focused, cost effective behavioral health services, Ms. Pattullo has grown Beacon into a company that manages more than seven million members in 14 states. Having lectured at both the Heller School at Brandeis University and Harvard University Medical School, Ms. Pattullo has more than 30 years of public and private sector management experience in complex and highly-charged environments. As executive director for Mental Health Management of America (MHMA), she administered the first and largest carve-out of mental health and substance use disorder services for Medicaid enrolled clients in the country. Under her leadership, MHMA improved treatment outcomes while reducing overall costs by $50 million. Ms. Pattullo earned her M.Ed. from Harvard University.
Follow Elizabeth Pattullo:
About Beacon Health Strategies: Beacon Health Strategies is engaged in the development and management of mental health and substance abuse programs for hospitals.
Christopher McCann
CEO & Co-Founder of Current Health
I left school at the age of 16 and graduated with a Masters in Computer Science at age 21. At 20, I set up my first company, Dizeo – this was in social networking for children. This failed in 2011 but the experience taught me some of the most valuable lessons of my life. Around the same time, I was spending time in hospitals due to an unwell relative. I decided to go to medical school as a result in 2012. In 2014, I founded snap40 as a direct result of my experiences working in hospital. I was part of the care of patients who had deteriorated avoidably because the warning signs were detected late. I wanted a world where myself and my family would be treated preventatively at the earliest possible point. snap40 prevent illness by automatically detecting those at high risk. We’re a software company who uses our own wearable device, worn on the upper arm of the patient, to continuously monitor them. We then do predictive analytics to identify the patient who needs medical attention most and bring healthcare to them, far earlier. Please get in touch! E-mail: christopher@snap40.com
Follow Christopher McCann:
About Current Health: We help healthcare reduce risk & cost by monitoring, managing and engaging patients at home.
Allen Lin
Co-Founder and CSO of Oncolinx
Follow Allen Lin:
About Harvard University, Oncolinx: Oncolinx is developing antibody-drug conjugates.
Shinta Nurfauzia
Co-Founder & CEO of Lemonilo
Shinta Nurfauzia is Co-Founder & CEO at Konsula.
Follow Shinta Nurfauzia:
About Lemonilo: Lemonilo is a curated marketplace for healthy food and cosmetics.
Ted Tieken
Founder and CEO of Keto and Co
Ted is the Founder and CEO of Keto and Co / Sated. Formerly cofounder and CTO of SittingAround.com
Follow Ted Tieken:
About Keto and Co, SittingAround: Keto and Co makes a growing line of ultra-low carb, ketogenic foods.
Rushika Fernandopulle
Co-Founder & Chief Executive Officer of Iora Health
Rushika Fernandopulle is Co-founder and CEO at Iora Health
Follow Rushika Fernandopulle:
About Health Rosetta Group, Iora Health: Iora Health is a healthcare company that helps patients manage their health and navigate the healthcare system.
Suelin Chen
CEO & Co-Founder of Cake
Suelin Chen is the CEO and co-founder of Cake (joincake.com), an online platform for advance care and end-of-life planning that is used by companies including Blue Cross Blue Shield of MA, Harvard Pilgrim, Liberty Mutual, and Massachusetts General Hospital. Suelin earned her BS and PhD from MIT, where she engineered new medical imaging technologies at a translational research lab at MGH. She served as the director of The Lab at Harvard, where she worked with student entrepreneurs and researchers at the Wyss Institute to commercialize their ideas. Suelin then worked as a transaction advisor to healthcare companies at IMS Health Capital before starting Cake.
Follow Suelin Chen:
About Cake: Cake is the world’s largest platform for helping people navigate end-of-life.
Mark Zhang
Co-Founder of Cake
Mark Zhang is the Medical Director of the Digital Innovation Hub at Brigham and Women’s Hospital, Associate Program Director of the Clinical Informatics and Innovation Fellowship at Partners Healthcare, and a Palliative Care consultant at Dana-Farber Cancer Institute. He is the founder of Palliative Care Fast Facts for iOS and Android mobile applications, the co-founder of Cake, a venture backed company focused on advance care planning, and also founded and was the first president of American Medical Informatics Association Clinical Informatics Fellows (ACIF), the national organization for clinical informatics fellows.
Follow Mark Zhang:
About Cake: Cake is the world’s largest platform for helping people navigate end-of-life.
Giulio Ruffini
President, CSO and co-founder of Neuroelectrics
Dr. Giulio Ruffini is the CEO and CTO of Starlab and the president and CSO of Neuroelectrics. He obtained a BA in Mathematics & Physics from Berkeley and a PhD in theoretical physics from UC Davis/LANL in 1995. In 2000 he founded Starlab to transform science into high-impact technologies.
12 years later he founded Neuroelectrics, a company which combines high-precision multichannel stimulation technologies with advanced biophysical and neuro-computational models.
For the past 15 years, Giulio has been developing technology for and researching the use of non-invasive brain monitoring and brain stimulation techniques, with a focus on EEG and transcranial current stimulation. His paper on brain-to-brain telepathy communication was the top 10 most shared papers of 2014. He is currently leading or involved in several European programs such as Galvani ERC Synergy, STIPED or Neurotwin.
Follow Giulio Ruffini:
About Neuroelectrics: Neuroelectrics is a digital brain health company that diagnoses and treats brain disorders with personalized neuromodulation, and improves overall brain health.
Dean Travers
Co-Founder & Chairman of Luminopia
Dean Travers is the Co-Founder & CEO at Odin.
Follow Dean Travers:
About Luminopia, Odin: Luminopia is pioneering a new class of treatments for significant neuro-visual disorders.
Scott Xiao
Co-Founder & CEO of Luminopia
Scott Xiao is the Co-Founder & CEO at Luminopia.
Follow Scott Xiao:
About Luminopia: Luminopia is pioneering a new class of treatments for significant neuro-visual disorders.
Michael Lin
Co-Founder & Executive Chairman of Reify Health
Michael Lin is the Co-Founder & Executive Chairman at Reify Health.
Follow Michael Lin:
About Reify Health: Reify Health is a cloud-based software company that develops tools for the clinical trial ecosystem.
Thomas Schuetz
Co-Founder of Audentes Therapeutics
Dr. Schuetz, M.D., Ph.D., is the co-founder of Audentes Therapeutics and has served as a member of the board of directors since July 2013. Dr. Schuetz also provided consulting services to Audentes from July 2012 to June 2013. Dr. Schuetz is currently the Chief Executive Officer of Compass Therapeutics, LLC. Previously, Dr. Schuetz was a Venture Partner at OrbiMed. Dr. Schuetz served as the Chief Medical Officer of Therion Biologics Corporation and the Vice President of Clinical Affairs at Transkaryotic Therapies, Inc. (now Shire Pharmaceuticals, Inc.). Dr. Schuetz has also served as the Chief Medical Resident at Massachusetts General Hospital and completed a medical oncology fellowship at the Dana-Farber Cancer Institute. Dr. Schuetz also serves on the board of directors of Relypsa, Inc. and Glypharma, Inc. Dr. Schuetz holds a B.S. in chemistry from Xavier University, an M.D. from Harvard Medical School and a Ph.D. in genetics from Harvard University. Dr. Schuetz is Board Certified in Medical Oncology.
Follow Thomas Schuetz:
About Audentes Therapeutics, Compass Therapeutics, Inc.: Audentes is a biotechnology company that employs gene therapy technology to develop treatments for people with rare muscle diseases.
Toni Oloko
Head of Business Development/Co-Founder of Orthly
Toni Oloko is the co-founder of Orthly. He was the founder and CEO of PracticeGigs.
Follow Toni Oloko:
About Dandy, Orthly: Orthly provides doctor-prescribed invisible aligner treatment that combines convenience and quality at less than half of the usual price.
Jonathan Bush
Founder and CEO of Zus Health
Jonathan Bush is the CEO and Founder of Zus Health. He is also the Chief Executive Officer, President, and Chairman of the Board of Directors. Mr. Bush co-founded athenahealth, Inc. in 1997 and has been a director since our inception. Prior to joining the Company, Mr. Bush served as an EMT for the City of New Orleans, was trained as a medic in the U.S. Army, and worked as a management consultant with Booz Allen & Hamilton. Mr. Bush obtained a Bachelor of Arts in the College of Social Studies from Wesleyan University and an M.B.A. from Harvard Business School.
Follow Jonathan Bush:
About Firefly Health, Zus Health: Zus Health helps a new wave of healthcare builders to create technologies and services without the usual blockers.
Venky Soundararajan
Co-Founder & Chief Scientific Officer of nference
Follow Venky Soundararajan:
About nference: nference.inc, provides an AI based software platform that synthesizes siloed biomedical knowledge for insights and makes it computable.
Gaurav Kaushik
Founder of Cascade.bio
Follow Gaurav Kaushik:
About Cascade.bio, ScienceIO: Cascade is rethinking how we interface with biomedical information, to accelerate therapeutic and clinical workflows.
Lara Yuan
Founder of Cascade.bio
Follow Lara Yuan:
About Cascade.bio: Cascade is rethinking how we interface with biomedical information, to accelerate therapeutic and clinical workflows.
Kevin Connors
Executive Director, Founder of Solace Therapeutics
Kevin Connors is an accomplished entrepreneur and venture investor. He has co-founded seven healthcare technology companies, and has had interim CEO roles in nine. These companies have focused on developing proprietary technology to address large un-met medical needs, such as emphysema, low back pain, cerebral aneurysm, and bladder dysfunction. Prior to founding Spray Venture Partners in 1996, Kevin was the founding CEO of Vesica Medical, a company focused on the surgical treatment of female urinary incontinence. Under this leadership, Vesica realized product sales within 18 months of formation and was acquired by Boston Scientific Corporation in 1995. Prior to Vesica, Kevin led medical device investment activity at DSV Partners in Newport Beach, California. Kevin is on the Board of Directors of the New England Venture Capital Association and MassMEDIC, the Massachusetts Medical Device Industry Council. He has served on the Board of Directors of Vesica Medical, Inc. (acquired by Boston Scientific), Masimo Corp., Pilot Cardiovascular (acquired by CR Bard), Circe Biomedical (acquired by ICN Pharmaceuticals), Gamera Bioscience (acquired by Tecan AG), and Endonetics (acquired by Medtronic). In addition to serving on our board, he also serves on the boards of, Facet Solutions, Leptos Biomedical, Solace Therapeutics, Highgate Orthopedics, and Cascade Ophthalmics. Kevin received a B.S. in Electrical Engineering from the University of Notre Dame, an M.S. in Electrical Engineering from the University of Dayton, and an M.B.A. from the Harvard Business School.
Follow Kevin Connors:
About AgenDx Biosciences, Solace Therapeutics, Spray Venture Partners: Solace Therapeutics develops and commercializes non-surgical office-based treatments for common bladder disorders.
Sumit Nagpal
Co-Founder of LumiraDx
Follow Sumit Nagpal:
About Cherish Health, HIMSS, HIMSS, LumiraDx: LumiraDx is a healthcare company that manufactures a diagnostic platform to support a menu of tests with lab comparable performance.
Alan D’Andrea
Co-Founder of Cedilla Therapeutics
Alan D’Andrea brings years of research insights into DNA repair pathways, oncoproteins and ubiquitin to Cedilla. A professor of radiation oncology at Harvard Medical School, Alan also serves as director of the Center for DNA Damage and Repair at Dana-Farber Cancer Institute. Alan’s research centers on the molecular signaling pathways that regulate the cellular response to DNA damage, with a particular focus on the pathogenesis of human chromosome instability and the identification of novel interacting proteins. Alan is a graduate of Harvard Medical School and a member of the National Academy of Medicine.
Follow Alan D’Andrea:
About Cedilla Therapeutics, Dana-Farber Cancer Institute: Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Laura D’Asaro
Co-Founder & CEO of Chirps Chips (Six Foods)
Follow Laura D’Asaro:
About Chirps Chips (Six Foods): Chirps Chips is a creating edible insect foods for healthyeating and sustainability.
Jo Viney
Co-Founder, President and Chief Scientific Officer of Pandion Therapeutics
Follow Jo Viney:
About Pandion Therapeutics: Pandion Therapeutics develops innovative modular proteins, antibodies, and bispecifics for autoimmune and inflammatory diseases.
Michael Greeley
Co-Founder & Partner of Flare Capital Partners
Michael Greeley was previously a General Partner at [Flybridge Capital Partners](http://www.crunchbase.com/financial-organization/flybridge-capital-partners) whose principle investment focus area is the application of “Big Data” platforms across a number of industry verticals. Michael is most excited about the convergence of healthcare and information technologies and the profound opportunities to transform healthcare. Michael is on the Board of Iora Health and Predilytics, and represented his previous firm on the boards of BlueTarp Financial, MicroCHIPs, PolyRemedy, Predictive Biosciences, SpringLeaf Therapeutics, T2 Biosystems, TARIS Biomedical, and VidSys and led the firm’s investment in lighterliving, Magen BioSciences and Protein Forest. Michael’s blog, On the Flying Bridge, can be found at www.ontheflyingbridge.com. You can follow him on Twitter at www.twitter.com/greels1. Michael founded IDG Ventures Atlantic in 2001 before it transitioned to Flybridge Capital Partners in 2008. Michael served on the board of International Data Group, the flagship Limited Partner for the IDG Ventures global network of funds. Previously, Michael was with Polaris Venture Partners, where he focused on both early-stage and later-stage financings for emerging growth companies. Before Polaris, Michael served as Senior Vice President and Founding Partner of GCC Investments, a $200 million private equity fund. Prior to GCC Investments, Michael was a Vice President and one of the early professionals at Wasserstein Perella & Co., an international merchant bank with a $1.0 billion private equity fund. Additionally, Michael was a member of the Mergers and Acquisitions Department of Morgan Stanley & Co. and worked in the Leveraged Buyout Group of Credit Suisse First Boston. In prior positions, Michael has served on the Boards of a number of public and private companies including FleetCor Technologies (NYSE: FLT), Global TeleSystems Group (NASDAQ: GTSG), El Sitio International (NASDAQ: LCTO), MotherNature.com (NASDAQ: MTHR), Crescent Communications (acquired by Clear Channel), and American Capital Access. Michael received a BA with honors in Chemistry from Williams College and an MBA from Harvard Business School.
Follow Michael Greeley:
About Flare Capital Partners: Flare Capital Partners provides capital for early-stage and emerging healthcare technology companies.
Uli Becker
Co-Founder of Aegle Gear
Uli Becker is Co-Founder of Aegle Gear. Uli is a business executive and investor that supports new businesses that challenge conventions. He also brings 25 years of sporting goods experience to the table. Having worked for adidas, he served in many executive roles including CMO for adidas, as well CEO and President of Reebok, to name a few.
Follow Uli Becker:
About Aegle Gear: Healthcare Apparel built to perform and protect
Jean Sommadossi
Founder & Chief Executive Officer of Idenix Pharmaceuticals
Jean-Pierre Sommadossi is a veteran in the field of biotechnology. Jean Sommadossi was the Principal Founder of Idenix Pharmaceuticals, Inc (NASDAQ: IDIX) and a co-Founder of Pharmasset, Inc (NASDAQ: VRUS), and served as Chairman and Chief Executive Officer of Idenix Pharmaceuticals from November 2000 to November 2010. From 1998 to November 2000, Jean Sommadossi has served as Chairman of the Board of Directors and then as Executive President and Chief Scientific Officer. Under his leadership, Idenix has raised more than $450 million in private and public equity financings and entered into multiple strategic partnerships, including those with Sumitomo and GlaxoSmithKline (GSK) as well as a landmark biotechpharma transaction with Novartis Pharma AG in 2003. Prior to founding Idenix, Jean Sommadossi was on the Faculty of The University of Alabama at Birmingham School of Medicine since March 1985. He has served as a Professor of Pharmacology, Toxicology and Clinical Pharmacology as well as an Associate Director of both the Center for AIDS Research and The Liver Center from June 1992 to November 2000. Jean Sommadossi has authored over 180 peer-reviewed publications and holds more than 50 US patents related to the treatment of Cancer and Infectious Diseases. Jean Sommadossi has earned his Pharm.D. and Ph.D. in Pharmacology degrees from the University of Marseilles in France. He was a postdoctoral Fogarty Fellow at the National Cancer Institute and the Medical College of Virginia and a recipient of a Faculty Award from The American Cancer Society. Jean Sommadossi currently is a Senior Advisor to PureTech Ventures. Jean Sommadossi was recently named to the Therapeutics Advisory Council of Harvard Medical School.
Follow Jean Sommadossi:
About Atea Pharmaceuticals, Idenix Pharmaceuticals: Idenix Pharmaceuticals is focused on the discovery and development of drugs for the treatment of human viral diseases.
Andrew Needleman
CEO & Founder of DoseSpot
Follow Andrew Needleman:
About Claricode, DoseSpot: E-Prescribing Integration Services
Todd MacLean
Co-Founder and Managing Partner of Silversmith Capital Partners
Todd has spent over 15 years as a growth equity investor prior to co-founding Silversmith Capital Partners. Todd joined Bain Capital Ventures in 2006, serving as a Managing Director upon his return to the firm in 2012 from Silicon Valley where he co-led the growth equity effort at Accel Partners. While at BCV, Todd focused on growth equity investments in the technology sector, with a particular emphasis on application SaaS and information services. Prior to BCV, Todd worked at Summit Partners as an Associate and later Vice President, as well as in operating roles at several private companies, including Synapse Group, the predecessor company to Priceline.com. Todd’s past investment experience includes Appriss (acquired by Insight Venture Partners), Ameritox, Archer (acquired by RSA/EMC), Dealer.com (acquired by Dealertrack), iPay (acquired by Jack Henry & Assoc.), SurveyMonkey, Wrike and Yapstone. He received an AB, cum laude, in English from Dartmouth College and an MBA with Honors from the Wharton School at the University of Pennsylvania. Todd lives with his wife and two children in Newton, MA where he serves on the Board of Trustees of The Park School in Brookline and is actively involved with Cradles to Crayons. He is an avid reader of modern fiction and is slowly sliding back into the misery of being a Red Sox fan that plagued his youth.
Follow Todd MacLean:
About Silversmith Capital Partners: Silversmith Capital Partners invests in technology and healthcare companies.
Jeff Crisan
Co-Founder and Managing Partner of Silversmith Capital Partners
Follow Jeff Crisan:
About Silversmith Capital Partners: Silversmith Capital Partners invests in technology and healthcare companies.
Jim Quagliaroli
Co-Founder & Managing Partner of Silversmith Capital Partners
Follow Jim Quagliaroli:
About Absorb LMS, impact.com, Just Women’s Sports, NRG eSports, PDFTron, Silversmith Capital Partners: Silversmith Capital Partners invests in technology and healthcare companies.
Robert Green
Co-Founder of Genome Medical
Follow Robert Green:
About Genome Medical: Genome Medical is a telegenomics technology and services company allowing access to genomic-based medicine.
Robert Coffin
Founder and CEO of Replimune Group
Robert Coffin is co-founder and CEO of Replimune. Previously he was Founder & CTO of BioVex Inc, a spin out from his research group at University College London in 1999. Rob was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC; Imlygic) and oversaw all research and clinical development including bringing T-VEC through to two pivotal phase 3 studies in melanoma and head & neck cancer. BioVex was acquired by Amgen in 2011 where Rob was VP Global Development until 2013. T-VEC was approved by the FDA for use in advanced melanoma in October 2015, the first oncolytic therapy or gene therapy to be approved in the US. Rob was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991.
Follow Robert Coffin:
About Replimune Group: Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.
Philip Sparke
Founder of Replimune Group
He also acted as the company’s Chairman from November 2009 until March 2011, when the company was acquired by Amgen for up to $1bn ($425m upfront). BioVex (now a subsidiary of Amgen) is based in Woburn, MA, USA and Abingdon, UK and develops biologics for solid tumours and prophylactic vaccines for infectious diseases. The Company’s lead program is completing Phase III testing for metastatic melanoma (study fully enrolled). Philip’s key responsibilities and achievements at Biovex include the successfully implemented exit strategy; the sale to Amgen represented one of the largest takeovers of a private VC backed biotech company in recent years. In 2005, Philip established Biovex’ US operations from scratch; recruiting the entire US senior management team (outside the CTO) whilst setting up all key functions including commercial capabilities. Arriving as the first employee in the US he grew the Company to 70 employees in Woburn, MA while retaining 30 in Abingdon, UK. Over the years, Philip executed five major private equity financings involving blue chip international investor syndicates totaling more than $160m including the second largest biotech VC raise of 2009 at $70m. He also oversaw the building of a launch grade manufacturing facility to zero default timelines and led his team through the agreement of a SPA with the FDA on the design of a pivotal study which commenced and was recruited on projected timeframes. Philip recently joined the Board of Directors of Oxyrane as Chairman.
Follow Philip Sparke:
About Elevate Investments, Forbion Capital Partners, Replimune Group, Replimune Group: Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.
Roy Schoenberg
Co-Founder, Chief Executive Officer & President of Amwell
Roy Schoenberg M.D., MPH founded American Well Inc. and serves as Chief Executive Officer and President of its American Well Systems. Roy Schoenberg founded Carekey, Inc. and served as its President. He served as a Senior Vice President and Chief Internet Solutions Officer at TriZetto, following its acquisition of CareKey in December 2005. He served as Senior Associate of the Center for Clinical Computing, Beth Israel Deaconess Medical Center, Harvard Medical School. He serves as a Director of American Well Corporation. Roy Schoenberg is a frequent speaker at the American Medical Informatics Association and other conferences. He has published a number of scientific papers in leading journals. In 1998, he joined the Harvard-MIT Fellowship Program in Clinical Informatics and earned an additional MPH in Healthcare Management from the Harvard School of Public Health. Roy Schoenberg completed his Medical Training (MD) at the Hebrew University of Jerusalem.
Follow Roy Schoenberg:
About Amwell: Amwell is a telehealth platform that provides its patients with more affordable, higher quality health care.
Ido Schoenberg
Co-Founder, Chairman, and Chief Executive Officer of Amwell
do serves as the Chairman and CEO of American Well Corporation and oversees the company’s corporate strategy. Ido has a lengthy track record of successfully leading technology companies in the healthcare field. In 1996, together with Phyllis Gotlib, he co-founded iMDSoft, a provider of enterprise software that automates hospital critical care units. He grew the company into a market leader with a large multi-national install base in the U.S., Europe, and East Asia. In 2001, Ido joined CareKey Inc. as Chief Executive Officer and took the company through its acquisition by the TriZetto group. Ido served as TriZetto’s Chief Business Strategy Officer until his departure in the summer of 2006. Ido received his MD from the Sackler School of Medicine.
Follow Ido Schoenberg:
About Amwell: Amwell is a telehealth platform that provides its patients with more affordable, higher quality health care.
Ian Brady
Co-Founder & CEO of AVA
Ian Brady is the Chief Executive Officer at Hologram Sciences.
Follow Ian Brady:
About AVA, Great Marsh Brewing Company, Hologram Sciences, Plenty: AVA is a personalized, data-driven nutritional coaching solution.
Ihsan Ecemis
Co-Founder & CTO of AVA
Ihsan Ecemis is the CTO at Hologram Sciences.
Follow Ihsan Ecemis:
About AVA, Hologram Sciences: AVA is a personalized, data-driven nutritional coaching solution.
Elliot Cohen
Co-Founder and Chief Product Officer of PillPack
Elliot Cohen is the Co-founder at PillPack.
Follow Elliot Cohen:
About Founder Collective, PillPack: PillPack is a full-service pharmacy that sorts medication by dose and offers door-to-door delivery.
David Coppins
Co-Founder and Chief Executive Officer of IntelyCare
David Coppins is co-founder and CEO of IntelyCare, the intelligent workforce management solution for post-acute healthcare facilities. Prior to starting IntelyCare, David served as president of Virgin Pulse, part of Sir Richard Branson’s Virgin Group. Before Virgin Pulse, David co-founded the college savings company Upromise in 1999. After Sallie Mae bought Upromise for $300M in 2006, David remained with the company and was later named CEO. Earlier in his career, David held various roles in business consulting and private equity at companies including Monitor Deloitte and Monitor Clipper Partners. David has a bachelor’s degree in business management from Brigham Young University.
Follow David Coppins:
About IntelyCare, Virgin Pulse: IntelyCare is revolutionizing healthcare staffing, scheduling, and training by offering an enterprise workforce management platform.
Craig Lund
Co Founder & CEO of Mightier
Craig Lund is a Co-Founder and Chief Executive Officer at Mightier.
Follow Craig Lund:
About Mightier: Mightier is a gaming platform and family program scientifically-proven to help kids regulate their emotions.
Jason Kahn
Founder, Chief Science Officer of Mightier
Dr Jason Kahn is the Chief Science Officer and co-founder of Neuromotion. He combines his expertise in developmental psychology and mental health to create video games that help children build emotional strength: the ability to harness their emotions to overcome behavioral challenges. Dr Kahn also holds an appointment at Boston Children’s Hospital and Harvard Medical School, where he creates and researches new technology addressing acute problems in pediatric mental health.
Follow Jason Kahn:
About Mightier: Mightier is a gaming platform and family program scientifically-proven to help kids regulate their emotions.
Alex Adeli
Founder/CEO of Stynt
Follow Alex Adeli:
About Stynt: Simplifying healthcare staffing to enhance the quality of patient care.
Jonathan Zhao
Co-Founder and Chairman of Hangzhou Just Biotherapeutics (Just China)
Asia strategy across small molecule, biologics and vaccine. He had also served as the interim head of Pfizer’s Bio-enhancement Development Unit during 2009-2010 in charge of the biosimilar and biobetter strategy development and business operation. Dr. Zhao received his B.S. in Pharmaceutical Sciences from Fudan University (Shanghai, China), PhD. magna cum laude in Analytical Chemistry from Ghent University (Ghent, Belgium), and MBA from Massachusetts Institute of Technology (Cambridge, USA). He has contributed more than 30 peer-reviewed publications and book chapters.
Follow Jonathan Zhao:
About Hangzhou Just Biotherapeutics (Just China), Transcenta: Hangzhou Just Biotherapeutics is a comprehensive high-tech design company.
Shanel Fields
Founder and CEO of MD Ally
As the child of a volunteer EMT, Shanel Fields was inspired by her father’s experiences as a first responder to launch a healthcare technology company in the 911 space that focuses on ensuring the appropriate use of finite emergency resources and improving long-term patient outcomes. In 2018, she leveraged her mobile and healthcare technology expertise to launch MD Ally, an EMS telemedicine platform that enables collaborative partnerships between public safety and provider organizations for large-scale mobile integrated healthcare initiatives. Shanel has found that driving innovation in the 911 space has fulfilled her desire to positively impact the world around her and improve the health of all citizens, particularly when they’re at their most vulnerable moments. Prior to launching MD Ally, Shanel attended Wharton Business School where she majored in Healthcare Management, Entrepreneurship and Innovation, as well as worked alongside life-long EMS researchers to study patient ER utilization and first responder advocacy. For more than a decade, she’s worked for innovative companies like AT&T and athenahealth, where she has scaled and led impact-focused growth teams focused on enterprise health systems, payers, and independent health entities.
Follow Shanel Fields:
About MD Ally: MD Ally is a telehealth company that enables a virtual response tier for 9-1-1.
Glenn Robertelli
Co-Founder & Chief Operating Officer of Admetsys
Follow Glenn Robertelli:
About Admetsys: For people at diabetic risk, glucose control is at its most crucial while in hospital or surgery.
Daphne Zohar
Founder, CEO of PureTech Health
Daphne Zohar is the founder and managing partner of PureTech, a technology development company tackling tomorrow’s biggest healthcare challenges. Ms. Zohar was recognized by Fierce Biotech as one of the “Top 10 Women in Biotech,” BioWorld as one of 28 leaders predicted to be the “movers and shakers” of the biotechnology industry over the next twenty years, and by the Boston Globe as one of the “Top 15 Innovators.” A successful entrepreneur, Ms. Zohar created PureTech and assembled a leading team to help implement her vision for the firm. She sits on the Boards of Directors of PureTech, Enlight (a cross disciplinary consortium of leading healthcare and pharma companies), Follica Inc., Akili Interactive Labs, Vedanta Bioscience, Mandara Sciences, Karuna Pharmaceuticals, and Tal Medical. She also sits on the Technology Development Fund Advisory Board at Children’s Hospital Boston and is an Editorial Advisor to Xconomy, a national technology news blog.
Follow Daphne Zohar:
About PureTech Health: PureTech Health is a bio pharma company and pushes the boundaries of medicine and changing and converging healthcare ecosystem.
Luk Vandenberghe
Co-Founder of GenSight Biologics
Follow Luk Vandenberghe:
About Affinia Therapeutics, Akouos, Broad Institute, GenSight Biologics, Grousbeck Gene Therapy Center, Harvard Medical School, Harvard University, Massachusetts Eye and Ear Infirmly: GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.
Daniel Palestrant
Founder & CEO of Par8o
Daniel Palestrant studied at Johns Hopkins, Duke University, and Harvard Medical School. He co-founded SERMO, the largest online physician community in the world, which was acquired in 2013.
Follow Daniel Palestrant:
About Par8o: The current healthcare crisis is a uniquely American challenge and ultimately will be solved with a uniquely American solution.
Mehmet Toner
Founder of Torpedo Diagnostics
Mehmet Toner is the Helen Andrus Benedict Professor of Bioengineering at the Massachusetts General Hospital, Harvard Medical School, and Harvard-MIT Health Sciences & Technology. He is internationally recognized for his research at the interface of nanotechnology, microsystems engineering, microfluidics, and applications in clinical medicine. Dr. Toner was born in Istanbul, Turkey. He obtained his undergraduate degree in mechanical engineering at the Istanbul Technical University, and his master’s degree and doctorate in Mechanical Engineering at MIT. He is the author of more than 300 original scientific and technical publications, and an inventor on more than 30 patents. Dr. Toner is a pioneer in the development of technologies to isolate extremely rare cells from blood, including circulating tumor cells. He is the founding Director of the NIH BioMicroElectroMechanical Systems Center, a nationwide center exploring the applications of microfluidics and nanotechnology in clinical medicine and life sciences. His work in cancer was awarded the Quantum grant from NIH as part of the “moon shot” program. His work has resulted in the formation of multiple companies servicing clinical diagnostics and biotechnology.
Follow Mehmet Toner:
About Massachusetts General Hospital, Torpedo Diagnostics: Torpedo Diagnostics is revolutionizing cancer detection, management and cure with a proprietary technology platform .
Ravi Kapur
Founder of Torpedo Diagnostics
Ravi Kapur is a scientist, engineer, and entrepreneur with 20 years of experience in developing and commercializing nascent technologies from academic laboratories. He is an Entrepreneur-in-Residence and directs the Innovation Team at Massachusetts General Hospital in Boston. He led the engineering team at MGH in development of the CTC-iChip. He has co-founded and built successful companies with innovative technology from MGH, MIT, Princeton, and Carnegie Mellon. He is currently the CEO of MicroMedicine Inc., a spinout from MGH. Dr. Kapur trained as a Bioengineer at Clemson University and cut his teeth in technology and product development at the United States Naval Research Laboratory in Washington DC.
Follow Ravi Kapur:
About Massachusetts General Hospital, Torpedo Diagnostics: Torpedo Diagnostics is revolutionizing cancer detection, management and cure with a proprietary technology platform .
Shyamala Maheswaran
Founder of Torpedo Diagnostics
Shyamala Maheswaran is an Associate Professor in Surgery at Harvard Medical School and the Scientific Director for the Center for Cancer Risk Assessment at the Massachusetts General Hospital. She is an authority in breast cancer biology and in molecular biology. Her long-term interest in the field of cancer biology has led to her leadership of collaborations with physicians, scientists and engineers, focused on the molecular applications of the CTC-iChip technology. Dr. Maheswaran graduated from the University of Peradeniya in Sri Lanka and received her doctorate in Biochemistry and Molecular Biology from Boston University, MA. Her research includes several high profile publications ranked in the top 1% of the academic field of Molecular Biology and Genetics based on a highly cited threshold for the field and publication year.
Follow Shyamala Maheswaran:
About Torpedo Diagnostics: Torpedo Diagnostics is revolutionizing cancer detection, management and cure with a proprietary technology platform .
Daniel Haber
Founder of Torpedo Diagnostics
Daniel Haber is the Director of Massachusetts General Hospital (MGH) Cancer Center, the Isselbacher/Schwartz Professor of Oncology at Harvard Medical School, and an investigator of the Howard Hughes Medical Institute (HHMI). He earned his BS and MS degrees from Massachusetts Institute of Technology (MIT), and his MD and PhD from Stanford. He completed his residency in internal medicine at MGH, his clinical fellowship in oncology at Dana Farber Cancer Institute, and his postdoctoral training at MIT, before joining the MGH faculty in 1991. Dr. Haber is known for his research in cancer genetics, including the discovery of genes implicated in the pediatric kidney cancer Wilms Tumor, the prevalence of founder BRCA mutations in young women of Ashkenazi descent. In 2004, his laboratory identified specific mutations in the epidermal growth factor receptor (EGFR) gene that underlie exquisite sensitivity to targeted kinase inhibitors, a milestone in the development of precision oncology targeting genetically-identified subsets of common epithelial cancers. The MGH Cancer Center now conducts a broad range of first-in-human clinical trials of targeted anti-cancer agents. Dr. Haber’s research is currently focused on the use of circulating tumor cells (CTCs) as a non-invasive “liquid biopsy” to detect and interrogate cancer cells at different stages of treatment response and disease progression, a project for which he and his close collaborator Dr. Mehmet Toner were awarded a Stand Up To Cancer Dream Team Award. Dr. Haber is a member of the National Academy of Medicine (Institute of Medicine), the American Academy of Arts and Science (AAAS), the Association of American Physicians (AAP), and the American Society for Clinical Investigation (ASCI).
Follow Daniel Haber:
About Torpedo Diagnostics: Torpedo Diagnostics is revolutionizing cancer detection, management and cure with a proprietary technology platform .
Chris Mason
Founder & Chief Scientific Officer of Avrobio
Chris Mason is the Founder & Chief Scientific Officer at AVROBIO .
Follow Chris Mason:
About Avrobio, Cell & Gene Therapy, Krystal Biotech, Ori Biotech, University College London (UCL): Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
Geoff MacKay
Founder, President & CEO of Avrobio
Geoff is a pioneer in cell and gene therapy with a track record of successful leadership at innovative biotechs. He is the former CEO of Organogenesis Inc., the world’s leading cell therapy company. During his tenure at the helm, the company treated 1 million patients with living cell therapies, received the first approval of an allogeneic cell therapy from the FDA’s Center for Biologics Evaluation and Research and led the field of regenerative medicine. Geoff is also the founding CEO of eGenesis, a biotech dedicated to applying CRISPR Cas-9 gene editing to xenotransplantation. Earlier in his career, Geoff spent 11 years at Novartis in senior leadership positions within the global transplantation and immunology franchise. Geoff sits on the boards of Talaris Therapeutics and Satellos Bioscience. Past activities include chairman of the board of MassBio, chairman of the board of the Alliance of Regenerative Medicine, and a member of the advisory council to the Health Policy Commission for Massachusetts.
Follow Geoff MacKay:
About Atlas Venture, Avrobio: Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
Jeffrey Medin
Scientific Founder of Avrobio
Jeffrey received his PhD in Biochemistry from the University of Kentucky. He then trained at the NIH working on gene transcription and gene transfer/therapy. He was recently a Senior Scientist at the University Health Network and a Full Professor at the University of Toronto. In January 2016, Jeffrey started a new position as the MACC Fund Endowed Professor in the Department of Pediatrics at the Medical College of Wisconsin in Milwaukee. He is also Vice Chair of Research Innovation for the Department of Pediatrics, Research Director within the Section of Pediatric Hematology/Oncology, and GMP Facility Director.
Follow Jeffrey Medin:
About Association of Pediatric Hematology/Oncology Nurses, Avrobio, GMP Securities, Medical College of Wisconsin: Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
Christopher Paige
Scientific Founder of Avrobio
Christopher earned a PhD in Immunology at the Sloan-Kettering Division of Cornell University Graduate School of Medical Sciences in 1979. He became a Member of the Basel Institute for Immunology in Switzerland in 1980 where he worked until joining the Ontario Cancer Institute as a Senior Scientist in 1987. In 1990, Christopher became the founding Director of the Arthritis and Autoimmunity Research Centre as well as Director of Research at The Wellesley Hospital. In 1997, he returned to OCI, now part of the University Health Network, to assume the role of Vice President, Research at UHN. Christopher is a Professor in the Departments of Medical Biophysics and Immunology at the University of Toronto.
Follow Christopher Paige:
About Avrobio, University of Toronto: Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
Elisabet de los Pinos
Founder and CEO of Aura Biosciences
Follow Elisabet de los Pinos:
About Aura Biosciences: Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Robin Smith
Founder & CEO of ORIG3N
Robin Y Smith is the Founder and CEO of ORIG3N, a biotechnology company developing a breakthrough disease-modeling platform targeting rare genetically inherited diseases and DNA testing solutions for Health and Wellness. Visit: www.orig3n.com
Follow Robin Smith:
About ORIG3N: ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Kate Blanchard
Chief Operating Officer / Founder of ORIG3N
Follow Kate Blanchard:
About ORIG3N: ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Jeffrey D. Wager
Co-Founder, Chairman & CEO of EnBiotix
Follow Jeffrey D. Wager:
About EnBiotix, Proterris: EnBiotix advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections.
Peter Hartzbech
Founder & CEO of iMotions A/S
Peter Hartzbech passion is global entrepreneurship and building companies. Driven by a desire to make a difference in the world, he embarked upon his entrepreneurial career by starting his first venture at the age of 25. Prior to founding iMotions, he worked in Ernst & Young Denmark and Venture Cup Denmark, where he advised start-up companies on business plans, strategic and financial issues. In December 2006, Peter was appointed by Red Herring Magazine as Top 25 under 35, where the Magazine appoints Notable Entrepreneurs under 35. Peter’s positive attitude and global vision have been the main driving forces behind iMotions’ rapid growth and expansion.
Follow Peter Hartzbech:
About iMotions A/S: iMotions A/S develops and provides biometric platforms, neuromarketing, psychology, VR, and engineering solutions.
Rudolf Jaenisch
Co-Founder of Fate Therapeutics
Rudolf Jaenisch is a founding member of the Whitehead Institute and a pioneer of developmental biology. He was the first to create a transgenic mouse, a technical achievement that changed the course of biomedical research by enabling the creation of animal models of human diseases. Dr. Jaenisch was also one of the first scientists to reprogram fully mature adult cells, like a skin cell, to become stem-like. Called induced pluripotent stem cells (iPSCs), this technology removed the dependence on embryos as a source of stem cells. At the Whitehead Institute, Dr. Jaenisch has been pursuing an understanding of epigenetic regulation and reprogramming, which has lead him to make principal discoveries in the field of stem cells. Dr. Jaenisch has coauthored more than 300 research papers, was appointed to the National Academy of Sciences and has received numerous prizes and recognitions, including First Peter Gruber Foundation Award in Genetics (2001), Robert Koch Prize for Excellence in Scientific Achievement (2002), BrupbacherFoundation Cancer Award (2003), Vilcek Prize (2007), and Massry Prize (2008).
Follow Rudolf Jaenisch:
About Fate Therapeutics, Fulcrum Therapeutics: Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
Romesh Subramanian
CEO and Founder of Dyne Therapeutics
Romesh Subramanian is the CEO and founder of Dyne Therapeutics.
Follow Romesh Subramanian:
About Dyne Therapeutics: Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Rich Gliklich
Founder and CEO of OM1
Rich Gliklich is the Founder and CEO at OM1.
Follow Rich Gliklich:
About Cyft, OM1: OM1 is a healthcare technology company that leverages real-world clinical data for medical research and personalized medicine.
